S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
NASDAQ:XGN

Exagen (XGN) Stock Forecast, Price & News

$2.42
-0.03 (-1.22%)
(As of 09/29/2023 ET)
Compare
Today's Range
$2.42
$2.54
50-Day Range
$2.24
$2.77
52-Week Range
$2.04
$4.20
Volume
5,033 shs
Average Volume
11,215 shs
Market Capitalization
$40.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.25

Exagen MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
158.3% Upside
$6.25 Price Target
Short Interest
Healthy
0.15% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.29
Upright™ Environmental Score
News Sentiment
0.59mentions of Exagen in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.62) to ($1.39) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.50 out of 5 stars

Medical Sector

167th out of 971 stocks

Medical Laboratories Industry

7th out of 25 stocks


XGN stock logo

About Exagen (NASDAQ:XGN) Stock

Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

XGN Price History

XGN Stock News Headlines

Exagen Inc. (NASDAQ:XGN) Short Interest Up 27.8% in September
Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
Exagen (NASDAQ:XGN) Stock Rating Reaffirmed by Cantor Fitzgerald
Exagen Inc. Reports Strong Second Quarter 2023 Results
Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
Exagen's Earnings Outlook
Exagen Inc. Appoints Paul Kim to Board of Directors
Cantor Fitzgerald Reaffirms Their Buy Rating on Exagen (XGN)
Exagen Inc. Reports First Quarter 2023 Results
Here's what Wall Street expects from Exagen's earnings
See More Headlines
Receive XGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exagen and its competitors with MarketBeat's FREE daily newsletter.

XGN Company Calendar

Last Earnings
8/07/2023
Today
10/01/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XGN
Fax
N/A
Employees
199
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.25
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+158.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-47,390,000.00
Pretax Margin
-66.94%

Debt

Sales & Book Value

Annual Sales
$45.56 million
Book Value
$2.61 per share

Miscellaneous

Free Float
10,655,000
Market Cap
$40.80 million
Optionable
Not Optionable
Beta
1.17
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Tina S. Nova Ph.D. (Age 69)
    Exec. Chairman of Board
    Comp: $65k
  • Mr. John Aballi (Age 38)
    CEO, Pres & Director
    Comp: $558.84k
  • Mr. Kamal Adawi M.S. (Age 44)
    MBA, CFO & Corp. Sec.
    Comp: $483.28k
  • Mr. Mark Hazeltine (Age 49)
    Chief Bus. Officer
    Comp: $483.28k
  • Ryan Douglas
    Investors Relations Officer
  • Mr. John Wegener (Age 54)
    Sr. VP of Sales and Marketing
  • Dr. Andrew L. Concoff FACR
    M.D., Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory Board
  • Dr. Michael I. Nerenberg M.D. (Age 68)
    Chief Medical Officer













XGN Stock - Frequently Asked Questions

Should I buy or sell Exagen stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Exagen in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" XGN shares.
View XGN analyst ratings
or view top-rated stocks.

What is Exagen's stock price forecast for 2023?

3 equities research analysts have issued 12 month price targets for Exagen's stock. Their XGN share price forecasts range from $5.00 to $7.00. On average, they expect the company's stock price to reach $6.25 in the next year. This suggests a possible upside of 158.3% from the stock's current price.
View analysts price targets for XGN
or view top-rated stocks among Wall Street analysts.

How have XGN shares performed in 2023?

Exagen's stock was trading at $2.40 at the start of the year. Since then, XGN stock has increased by 0.8% and is now trading at $2.42.
View the best growth stocks for 2023 here
.

Are investors shorting Exagen?

Exagen saw a increase in short interest in September. As of September 15th, there was short interest totaling 12,400 shares, an increase of 27.8% from the August 31st total of 9,700 shares. Based on an average trading volume of 15,100 shares, the days-to-cover ratio is currently 0.8 days. Currently, 0.2% of the company's stock are sold short.
View Exagen's Short Interest
.

When is Exagen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our XGN earnings forecast
.

How were Exagen's earnings last quarter?

Exagen Inc. (NASDAQ:XGN) issued its earnings results on Monday, August, 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.48) by $0.20. The business had revenue of $14.14 million for the quarter, compared to the consensus estimate of $10.97 million. Exagen had a negative trailing twelve-month return on equity of 74.00% and a negative net margin of 66.41%.

What guidance has Exagen issued on next quarter's earnings?

Exagen updated its third quarter 2023 earnings guidance on Monday, August, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $10.00 million-$10.50 million, compared to the consensus revenue estimate of $11.76 million.

What is Ron Rocca's approval rating as Exagen's CEO?

5 employees have rated Exagen Chief Executive Officer Ron Rocca on Glassdoor.com. Ron Rocca has an approval rating of 80% among the company's employees.

When did Exagen IPO?

(XGN) raised $50 million in an IPO on Thursday, September 19th 2019. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. Cowen, Cantor and William Blair served as the underwriters for the IPO.

What is Exagen's stock symbol?

Exagen trades on the NASDAQ under the ticker symbol "XGN."

How do I buy shares of Exagen?

Shares of XGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Exagen's stock price today?

One share of XGN stock can currently be purchased for approximately $2.42.

How much money does Exagen make?

Exagen (NASDAQ:XGN) has a market capitalization of $40.80 million and generates $45.56 million in revenue each year. The company earns $-47,390,000.00 in net income (profit) each year or ($2.02) on an earnings per share basis.

How many employees does Exagen have?

The company employs 199 workers across the globe.

How can I contact Exagen?

Exagen's mailing address is 1261 Liberty Way Suite C, VISTA CA, 92081. The official website for the company is www.exagen.com. The company can be reached via phone at 760-560-1501 or via email at ir@exagen.com.

This page (NASDAQ:XGN) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -